IA
AVIR icon

IndexIQ Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

IndexIQ Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$407K Buy
+56,439
New +$383K 0.01% 571

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IndexIQ Advisors's AVIR Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Atea Pharmaceuticals (AVIR) in Q1 2022: 56,439 shares worth $407K. The stake represents 0.01% of the portfolio and ranks #571 among its holdings.

127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

  • IndexIQ Advisors held 56,439 shares of Atea Pharmaceuticals worth $407K as of Q1 2022.
  • Atea Pharmaceuticals was a new IndexIQ Advisors position in Q1 2022.
  • Atea Pharmaceuticals made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #571 holding.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.